Leukemia - Table of Contents alert Volume 29 Issue 8

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 29, Issue 8 (August 2015) In this issue Review Concise Review Original Articles Letters To The Editor Corrigendum Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement We are pleased to announce that the Impact Factor* for Leukemia is now 10.431 - an increase from 9.379 last year. LEU is ranked 9 of 211 titles in the oncology category and 3 of 68 in the hematology category. The journal would like to thank all our authors, reviewers and readers for their continued support. (*Thomson Reuters 2014 Journal Citation Reports®)  »Submit your research    Review Top The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia J Eswaran, P Sinclair, O Heidenreich, J Irving, L J Russell, A Hall, D P Calado, C J Harrison and J Vormoor Leukemia 2015 29: 1623-1631; advance online publication, May 6, 2015; 10.1038/leu.2015.113 Abstract | Full Text Concise Review Top The DEK oncoprotein and its emerging roles in gene regulation C Sandén and U Gullberg Leukemia 2015 29: 1632-1636; advance online publication, March 13, 2015; 10.1038/leu.2015.72 Abstract | Full Text Original Articles Top ACUTE MYELOGENOUS LEUKEMIA CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia S S Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, J J D Morrissette, J Scholler, D Song, D L Porter, M Carroll, C H June and S Gill Leukemia 2015 29: 1637-1647; advance online publication, February 27, 2015; 10.1038/leu.2015.52 Abstract | Full Text ACUTE LYMPHOBLASTIC LEUKEMIA Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment C Eckert, N Hagedorn, L Sramkova, G Mann, R Panzer-Grümayer, C Peters, J-P Bourquin, T Klingebiel, A Borkhardt, G Cario, J Alten, G Escherich, K Astrahantseff, K Seeger, G Henze and A von Stackelberg Leukemia 2015 29: 1648-1655; advance online publication, March 9, 2015; 10.1038/leu.2015.59 Abstract | Full Text KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia OPEN K Malinowska-Ozdowy, C Frech, A Schönegger, C Eckert, G Cazzaniga, M Stanulla, U zur Stadt, A Mecklenbräuker, M Schuster, D Kneidinger, A von Stackelberg, F Locatelli, M Schrappe, M A Horstmann, A Attarbaschi, C Bock, G Mann, O A Haas and R Panzer-Grümayer Leukemia 2015 29: 1656-1667; advance online publication, April 28, 2015; 10.1038/leu.2015.107 Abstract | Full Text CHRONIC MYELOGENOUS LEUKEMIA A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia D W Woessner, A M Eiring, B J Bruno, M S Zabriskie, K R Reynolds, G D Miller, T O'Hare, M W Deininger and C S Lim Leukemia 2015 29: 1668-1675; advance online publication, February 27, 2015; 10.1038/leu.2015.53 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis J Wild, B J Schmiedel, A Maurer, S Raab, L Prokop, S Stevanović, D Dörfel, P Schneider and H R Salih Leukemia 2015 29: 1676-1683; advance online publication, February 24, 2015; 10.1038/leu.2015.50 Abstract | Full Text LYMPHOMA IL10 receptor is a novel therapeutic target in DLBCLs W Béguelin, S Sawh, N Chambwe, F C Chan, Y Jiang, J-W Choo, D W Scott, A Chalmers, H Geng, L Tsikitas, W Tam, G Bhagat, R D Gascoyne and R Shaknovich Leukemia 2015 29: 1684-1694; advance online publication, March 3, 2015; 10.1038/leu.2015.57 Abstract | Full Text Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma G Hess, U Keller, C W Scholz, M Witzens-Harig, J Atta, C Buske, S Kirschey, C Ruckes, C Medler, C van Oordt, W Klapper, M Theobald and M Dreyling Leukemia 2015 29: 1695-1701; advance online publication, March 13, 2015; 10.1038/leu.2015.60 Abstract | Full Text Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 L Li, P Pongtornpipat, T Tiutan, S L Kendrick, S Park, D O Persky, L M Rimsza, S D Puvvada and J H Schatz Leukemia 2015 29: 1702-1712; advance online publication, April 17, 2015; 10.1038/leu.2015.99 Abstract | Full Text MULTIPLE MYELOMA The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma OPEN X Papanikolaou, D Alapat, A Rosenthal, C Stein, J Epstein, R Owens, S Yaccoby, S Johnson, C Bailey, C Heuck, E Tian, A Joiner, F van Rhee, R Khan, M Zangari, Y Jethava, S Waheed, F Davies, G Morgan and B Barlogie Leukemia 2015 29: 1713-1720; advance online publication, March 10, 2015; 10.1038/leu.2015.65 Abstract | Full Text Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma E K Mai, U Bertsch, J Dürig, C Kunz, M Haenel, I W Blau, M Munder, A Jauch, B Schurich, T Hielscher, M Merz, B Huegle-Doerr, A Seckinger, D Hose, J Hillengass, M S Raab, K Neben, H-W Lindemann, M Zeis, C Gerecke, I G H Schmidt-Wolf, K Weisel, C Scheid, H Salwender and H Goldschmidt Leukemia 2015 29: 1721-1729; advance online publication, March 19, 2015; 10.1038/leu.2015.80 Abstract | Full Text STEM CELL BIOLOGY AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation X N Gao, F Yan, J Lin, L Gao, X L Lu, S C Wei, N Shen, J X Pang, Q Y Ning, Y Komeno, A L Deng, Y H Xu, J L Shi, Y H Li, D E Zhang, C Nervi, S J Liu and L Yu Leukemia 2015 29: 1730-1740; advance online publication, March 2, 2015; 10.1038/leu.2015.56 Abstract | Full Text The Notch ligand DLL4 specifically marks human hematoendothelial progenitors and regulates their hematopoietic fate V Ayllón, C Bueno, V Ramos-Mejía, O Navarro-Montero, C Prieto, P J Real, T Romero, M J García-León, M L Toribio, A Bigas and P Menendez Leukemia 2015 29: 1741-1753; advance online publication, March 17, 2015; 10.1038/leu.2015.74 Abstract | Full Text STEM CELL TRANSPLANTATION Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies R F Olsson, B R Logan, S Chaudhury, X Zhu, G Akpek, B J Bolwell, C N Bredeson, C C Dvorak, V Gupta, V T Ho, H M Lazarus, D I Marks, O T H Ringdén, M C Pasquini, J R Schriber and K R Cooke Leukemia 2015 29: 1754-1762; advance online publication, March 16, 2015; 10.1038/leu.2015.75 Abstract | Full Text MECHANISMS OF RESISTANCE F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance S P Gorantla, K Zirlik, A Reiter, C Yu, A L Illert, N Von Bubnoff and J Duyster Leukemia 2015 29: 1763-1770; advance online publication, March 12, 2015; 10.1038/leu.2015.70 Abstract | Full Text ANIMAL MODELS Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice R K Hyde, L Zhao, L Alemu and P P Liu Leukemia 2015 29: 1771-1778; advance online publication, March 6, 2015; 10.1038/leu.2015.58 Abstract | Full Text Letters To The Editor Top Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy X Chen, L F Newell, H Xie, R B Walter, J M Pagel, V K Sandhu, P S Becker, P C Hendrie, J L Abkowitz, F R Appelbaum and E H Estey Leukemia 2015 29: 1779-1780; advance online publication, February 4, 2015; 10.1038/leu.2015.23 Full Text Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells OPEN C Riether, T Gschwend, A-L Huguenin, C M Schürch and A F Ochsenbein Leukemia 2015 29: 1781-1785; advance online publication, February 4, 2015; 10.1038/leu.2015.26 Full Text Cellular origin of prognostic chromosomal aberrations in AML patients H Mora-Jensen, J Jendholm, N Rapin, M K Andersen, A S Roug, F O Bagger, L Bullinger, O Winther, N Borregaard, B T Porse and K Theilgaard-Mönch Leukemia 2015 29: 1785-1789; advance online publication, February 11, 2015; 10.1038/leu.2015.30 Full Text The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum S Momose, S Weißbach, J Pischimarov, T Nedeva, E Bach, M Rudelius, E Geissinger, A M Staiger, G Ott and A Rosenwald Leukemia 2015 29: 1789-1791; advance online publication, February 12, 2015; 10.1038/leu.2015.34 Full Text Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells L Lu, V A Saunders, T M Leclercq, T P Hughes and D L White Leukemia 2015 29: 1792-1794; advance online publication, February 13, 2015; 10.1038/leu.2015.35 Full Text Characterisation of a compound in-cis GATA2 germline mutation in a pedigree presenting with myelodysplastic syndrome/acute myeloid leukemia with concurrent thrombocytopenia C N Hahn, P J Brautigan, C-E Chong, A Janssan, P Venugopal, Y Lee, A E Tims, M S Horwitz, M Klingler-Hoffmann and H S Scott Leukemia 2015 29: 1795-1797; advance online publication, February 13, 2015; 10.1038/leu.2015.40 Full Text Corrigendum Top Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells H Dolatshad, A Pellagatti, M Fernandez-Mercado, B H Yip, L Malcovati, M Attwood, B Przychodzen, N Sahgal, A A Kanapin, H Lockstone, L Scifo, P Vandenberghe, E Papaemmanuil, C W J Smith, P J Campbell, S Ogawa, J P Maciejewski, M Cazzola, K I Savage and J Boultwood Leukemia 2015 29: 1798; 10.1038/leu.2015.178 Full Text Advertisement Nature Communications is now fully open access All new submissions if accepted, will be published open access and an article processing charge will apply. For more information visit the website. Visit our open access funding page or contact openaccess@nature.com to learn more on APC funding. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.